Table of Contents
ISRN Obstetrics and Gynecology
Volume 2012 (2012), Article ID 512732, 5 pages
Clinical Study

A High Dose Intravenous Immunoglobulin Therapy for Women with Four or More Recurrent Spontaneous Abortions

1Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
2Department of Obstetrics, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan
3KKR Sapporo Medical Center, Sapporo, Japan
4Mommy’s Clinic Chitose, Chitose, Japan

Received 15 March 2012; Accepted 7 August 2012

Academic Editors: K. Chan, J. M. Goldberg, and R. G. Lea

Copyright © 2012 Hideto Yamada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recurrent spontaneous abortion (RSA) may have immunological etiology. The aim of this study was to assess the efficacy of a high dose intravenous immunoglobulin (HIVIg) therapy, in which 20 g of intact type immunoglobulin was infused daily for 5 days during early gestation, for women who had a history of four or more consecutive spontaneous abortions of unexplained etiology. A total of 60 pregnant RSA women underwent HIVIg therapy, and the pregnancy outcome was assessed. The live birth rate was 73.3% (44/60). Fifteen pregnancies ended in spontaneous abortion, and one ended in intrauterine fetal death. In 11 of the 15 spontaneous abortions, fetuses had abnormal chromosome karyotype. When the 11 pregnancies with abnormal chromosome karyotype were excluded, the live birth rate was as high as 89.8% (44/49). The HIVIg therapy may be effective for severe cases of unexplained RSA.